Study maps vaccine for deadly pathogenic fungus

May 31, 2012

University of Alberta researchers have made breakthrough use of 3-D magnetic resonance technology to map the structure of a common fungus that is potentially deadly for individuals with impaired immune function. The work could pave the way for development of an effective vaccine.

The researchers targeted Candida, a pathogen that in its most virulent form has led to more than 70,000 in North American . Health officials estimate that death rate from this bloodstream infection is 40 per cent.

Lead U of A researchers Margaret Johnson and David Bundle as well as collaborators, at the Alberta Glycomics Centre, used for a three-dimensional examination of the fungus at an that measures less than 100 millionth of a centimetre.

The process, called molecular recognition allowed researchers to examine carbohydrate and antibody molecules related to the fungus to determine what sort of vaccine can best combat Candida.

Johnson described the three-dimensional approach to vaccinology as giving researchers a clear picture of how a vaccine must physically fit against the surface of the fungus.

The researchers used their findings to design test vaccines that produced positive results in containing the fungus. "Our multi-pronged strategy allowed us to observe a new type of molecular recognition," she said.

Johnson added if the private sector chooses to complete the development of a vaccine it could be 10 years before the drug is available.

Johnson and Bundle were assisted by U of A researcher Jonathan Cartmell and colleagues at the National University of Ireland and University of Georgia. The research was published May 25 in the .

Explore further: Chemical biologists find new halogenation enzyme

add to favorites email to friend print save as pdf

Related Stories

Johnson & Johnson plans to buy Dutch vaccine group

Sep 17, 2010

US cosmetics and pharmaceutical giant Johnson & Johnson said on Friday it intended to acquire a Dutch vaccine maker Crucell which is active in developing countries for about 1.75 billion euros.

Fatal fungal infections resist newest class of drugs

Sep 07, 2011

Fungi that cause severe infections in those with compromised immune systems are resisting the action of the latest group of antifungal drugs. Uncovering their strategies for doing this will lead to more effective treatments, ...

Recommended for you

Chemical biologists find new halogenation enzyme

10 hours ago

Molecules containing carbon-halogen bonds are produced naturally across all kingdoms of life and constitute a large family of natural products with a broad range of biological activities. The presence of halogen substituents ...

Protein secrets of Ebola virus

16 hours ago

The current Ebola virus outbreak in West Africa, which has claimed more than 2000 lives, has highlighted the need for a deeper understanding of the molecular biology of the virus that could be critical in ...

Protein courtship revealed through chemist's lens

16 hours ago

Staying clear of diseases requires that the proteins in our cells cooperate with one another. But, it has been a well-guarded secret how tens of thousands of different proteins find the correct dancing partners ...

Decoding 'sweet codes' that determine protein fates

18 hours ago

We often experience difficulties in identifying the accurate shape of dynamic and fluctuating objects. This is especially the case in the nanoscale world of biomolecules. The research group lead by Professor Koichi Kato of ...

Conjecture on the lateral growth of Type I collagen fibrils

Sep 12, 2014

Whatever the origin and condition of extraction of type I collagen fibrils, in vitro as well as in vivo, the radii of their circular circular cross sections stay distributed in a range going from 50 to 100 nm for the most ...

User comments : 0